One case study found that in the FIGO stages of ovarian cancer (Shepherd, 1989), the expression levels of RhoA mRNA were significantly higher in stage III-IV tumors than in stage I-II (Ellenbroek and Collard, 2007). This evidence concerns the gene RHOA and ovarian cancer.